D. E. Shaw & Co. Inc. Takes Position in Indivior PLC (NASDAQ:INDV)

D. E. Shaw & Co. Inc. purchased a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 99,606 shares of the company's stock, valued at approximately $1,238,000. D. E. Shaw & Co. Inc. owned 0.07% of Indivior at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Deerfield Management Company L.P. Series C grew its stake in Indivior by 74.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after purchasing an additional 3,790,518 shares during the period. Claret Asset Management Corp purchased a new position in shares of Indivior in the 4th quarter worth about $9,304,000. CenterBook Partners LP grew its position in Indivior by 105.5% during the fourth quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock valued at $14,268,000 after buying an additional 589,158 shares during the period. Marshall Wace LLP grew its position in Indivior by 659.7% during the fourth quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock valued at $6,299,000 after buying an additional 440,072 shares during the period. Finally, Foursixthree Capital LP purchased a new stake in Indivior during the fourth quarter worth about $4,639,000. 60.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on INDV shares. RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of Indivior in a report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock. Finally, Piper Sandler reduced their price objective on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a report on Thursday, March 6th.

Indivior Stock Performance

Shares of Indivior stock opened at $11.21 on Friday. The stock has a market capitalization of $1.55 billion, a P/E ratio of -32.03 and a beta of 0.98. Indivior PLC has a 52-week low of $7.33 and a 52-week high of $18.59. The stock's 50-day simple moving average is $10.24 and its 200 day simple moving average is $10.68.

Indivior (NASDAQ:INDV - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.19. The firm had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. Equities research analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.